Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Neurogene Inc. (NGNE)
Company Research
Source: Business Wire
100% of participants enrolled in Embolden™ registrational trial and 50% of participants dosed; on track to complete dosing in second quarter of 2026NGN-401 has been generally well-tolerated in Phase 1/2 trial and Embolden, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026FDA Breakthrough Therapy designation granted to NGN-401 based on positive interim safety and efficacy data from Phase 1/2 trialPPQ campaign planned to begin mid-2026, supporting BLA readinessStrong cash position provides runway through first quarter of 2028 NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced full year 2025 financial results and highlighted recent corporate updates.“We continue to demonstrate strong execution, with completion of enrollment in the Embolden registrational trial, dosing more than half
Show less
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates [Yahoo! Finance]Yahoo! Finance
- Neurogene to Participate in Stifel 2026 Virtual CNS ForumBusiness Wire
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Neurogene (NGNE) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $200.00 price target on the stock.MarketBeat
NGNE
Earnings
- 3/24/26 - Miss
NGNE
Sec Filings
- 3/24/26 - Form S-8
- 3/24/26 - Form 10-K
- 3/24/26 - Form 8-K
- NGNE's page on the SEC website